Basic Information
| LncRNA/CircRNA Name | PCAN-R1 |
| Synonyms | PCAT6, KDM5B-AS1, KDM5BAS1, PCAN-R1, ncRNA-a2, onco-lncRNA-96 |
| Region | GRCh38_1:202810954-202812156 |
| Ensemble | ENSG00000228288 |
| Refseq | NR_046325 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | RNA-seq, Microarray, qPCR, RNAi, Northern blot etc. |
| Sample | prostate cancer tissues, cell lines (LNCaP, CWR22Rv1, PC3 etc.) |
| Expression Pattern | up-regulated |
| Function Description | Both lncRNA showed positive correlation between gene expression and SCNA. The criteria of increasing expression from normal to primary to metastatic prostate cancer aimed to uncover lncRNA that may be important therapeutic targets for both primary and metastatic cancers. |
| Pubmed ID | 23728290 |
| Year | 2013 |
| Title | Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. |
External Links
| Links for PCAN-R1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |